Clinical trial
BATTLE Program: Sorafenib in Patients With NSCLC
NCT00411671 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00411671 |
|---|---|
| Title | BATTLE Program: Sorafenib in Patients With NSCLC |
| Official title | A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | United States Department of Defense U.S. Fed Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Sorafenib |
| Enrollment | 105 |
| Start date | Nov 1, 2006 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Dec 14, 2006 |
| Last update posted | Feb 11, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: